Literature DB >> 28895866

Specific immunotypes of canine T cell lymphoma are associated with different outcomes.

Nariman Deravi1, Olaf Berke2, J Paul Woods3, Dorothee Bienzle4.   

Abstract

Canine lymphoma is a heterogeneous disease with many different subtypes. Lymphoma of T cell type in particular is variable in outcome, and includes subtypes with non-progressive, slowly- and rapidly-progressive disease course. Association of immunotype with disease course is incompletely defined. Here, results of flow cytometric immunotyping of 127 canine T cell lymphomas were analyzed in relation to survival and progression free interval. Samples originated from 101 multicentric, 8 mediastinal, 6 cutaneous, 5 hepatosplenic, 5 gastrointestinal and 2 other anatomic subtypes of T cell lymphoma. Compared to multicentric T cell lymphoma, gastrointestinal lymphoma had shorter survival and progression free interval, and hepatosplenic lymphoma had shorter survival. Among dogs with multicentric T cell lymphoma, immunotypes of CD4+/CD8-/MHCII+, CD4-/CD8+/MHCII+ and CD4-/CD8+/MHCII- were associated with longer survival times than the immunotype of CD4+/CD8-/MHCII-, and immunotypes of CD4+/CD8-/MHCII+, CD4-/CD8+/MHCII-, and CD4-/CD8-/MHCII+ were associated with longer progression free intervals. Dogs with multicentric T cell lymphoma and concurrent leukemia had shorter survival but similar progression free interval compared to those without leukemia. Body weight, sex, hypercalcemia, cell size, expression of CD3 and use of combination or single agent chemotherapy did not significantly affect outcome of multicentric TCL.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Dog; Flow cytometry; Lymphosarcoma; Progression free interval; Survival

Mesh:

Year:  2017        PMID: 28895866     DOI: 10.1016/j.vetimm.2017.07.008

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  7 in total

1.  Composite lymphoma of concurrent T zone lymphoma and large cell B cell lymphoma in a dog.

Authors:  Arata Matsuyama; Dorothee Bienzle; Danielle Richardson; Nariman Deravi; Mei-Hua Hwang; Nikos Darzentas; Stefan M Keller
Journal:  BMC Vet Res       Date:  2019-11-16       Impact factor: 2.741

2.  RNA disruption indicates CHOP therapy efficacy in canine lymphoma.

Authors:  Amadeo M Parissenti; Laura B Pritzker; Baoqing Guo; Rashmi Narendrula; Shirly Xiaohui Wang; Lin Laura Lin; Jingchun Pei; Karolina Skowronski; Dorothee Bienzle; J Paul Woods; Kenneth P H Pritzker; Brenda L Coomber
Journal:  BMC Vet Res       Date:  2019-12-16       Impact factor: 2.741

3.  Use of immune repertoire sequencing to resolve discordant microscopic and immunochemical findings in a case of T cell-rich large B cell lymphoma in a young dog.

Authors:  Gary Kwok Cheong Lee; Dorothee Bienzle; Stefan Matthias Keller; Mei-Hua Hwang; Nikos Darzentas; Haiyang Chang; Emily Rätsep; Rebecca Egan; Janet Beeler-Marfisi
Journal:  BMC Vet Res       Date:  2021-02-18       Impact factor: 2.741

Review 4.  Flow Cytometry in the Diagnosis of Canine T-Cell Lymphoma.

Authors:  Stefano Comazzi; Fulvio Riondato
Journal:  Front Vet Sci       Date:  2021-04-21

5.  RNA-Seq analysis of gene expression in 25 cases of canine lymphoma undergoing CHOP chemotherapy.

Authors:  Miles W Mee; Sydney Faulkner; Geoffrey A Wood; J Paul Woods; Dorothee Bienzle; Brenda L Coomber
Journal:  BMC Res Notes       Date:  2022-03-22

6.  Clinical and Clinical Pathological Presentation of 310 Dogs Affected by Lymphoma with Aberrant Antigen Expression Identified via Flow Cytometry.

Authors:  Elena Celant; Laura Marconato; Damiano Stefanello; Pierangelo Moretti; Luca Aresu; Stefano Comazzi; Valeria Martini
Journal:  Vet Sci       Date:  2022-04-13

7.  Ki-67 assessment-agreeability between immunohistochemistry and flow cytometry in canine lymphoma.

Authors:  Antonella Rigillo; Andrea Fuchs-Baumgartinger; Silvia Sabattini; Ondrej Škor; Chiara Agnoli; Ilse Schwendenwein; Giuliano Bettini; Barbara C Rütgen
Journal:  Vet Comp Oncol       Date:  2021-04-07       Impact factor: 2.613

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.